Relvar Ellipta inhaler

Relvar Ellipta is a prescription medication used for the long-term treatment of asthma and chronic obstructive pulmonary disease (COPD). The Ellipta device is a specialized dry powder inhaler that delivers a combination of fluticasone furoate and vilanterol. The brand was developed through a strategic collaboration between GlaxoSmithKline (GSK) and Innoviva (formerly Theravance).

Manufacturing of the Relvar Ellipta inhalers primarily takes place in the United Kingdom, specifically at GSK's specialized respiratory manufacturing facilities in Ware. The product is distributed globally under various names, including Breo Ellipta in North America, while remaining under the ultimate ownership of GSK.

GSK, headquartered in London, is a global biopharmaceutical leader with a strong legacy in respiratory medicine. The company oversees the entire lifecycle of the product, from research and development to global supply chain management, ensuring that patients worldwide have access to this critical respiratory therapy.